The APEX data are strong and the NDA submission timeline is near-term (June 2026), which de-risks the regulatory path. However, historical T+20 performance on prior COGT reports has been poor (avg -7.67%), suggesting the market may already price in approval expectations. Traders should watch for FDA acceptance of the NDA and any AdCom vote as the next catalysts. Consider taking profits on any pre-NDA run-up.
Price Chart
Executive Summary
Cogent Biosciences reported updated Phase 2 APEX trial results for bezuclastinib in advanced systemic mastocytosis (AdvSM) at EHA 2026, showing a 65% objective response rate per mIWG criteria and 81% per PPR criteria, with 91% of patients achieving ≥50% reduction in KIT D816V variant allele frequency. The company plans to submit an NDA in June 2026 and expects commercial launch later this year. The data are clinically compelling and support a clear path to regulatory approval, but the stock has historically not responded positively to prior positive readouts (average T+20 return -7.67% on prior reports).
Key Facts
- Updated APEX trial data: 65% ORR per mIWG criteria (CR+CRh+PR+CI) and 81% ORR per PPR criteria in AdvSM patients.
- 91% of patients achieved ≥50% reduction in KIT D816V variant allele frequency; 89% had ≥50% reduction in bone marrow mast cells or clearance of aggregates.
- 12-month PFS rate of 79% and 12-month OS rate of 87%.
- NDA submission for bezuclastinib in AdvSM planned for June 2026.
- Company expects commercial launch in both systemic mastocytosis and GIST later this year following FDA approval.
- Safety profile manageable: most common TRAEs were hair color change (31%), neutropenia (31%), altered taste (28%), thrombocytopenia (25%), and ALT/AST elevations (21%), mostly low-grade.
Financial Impact
No financial data provided; bezuclastinib is Cogent's lead asset and potential approval would transform the company from pre-revenue to commercial-stage. Systemic mastocytosis and GIST represent multi-billion-dollar market opportunities.
Risk Factors
- FDA could issue a Complete Response Letter (CRL) on CMC or clinical grounds, delaying approval.
- Competition from approved KIT inhibitors (e.g., avapritinib) could limit commercial uptake.
- Stock has historically sold off after positive data releases (avg T+20 -7.67% on prior reports).
- Commercial launch execution risk for a first-time product.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311014 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $41.53 $35.28 | ▼ −15.05% | ▼ −14.13% | $31.02 (−25.31%) |
Aug 10, 2026 7w ago | Press Release | $41.53 $35.28 | ▼ −15.05% | ▼ −14.13% | $31.02 (−25.31%) |
Aug 9, 2026 7w ago | Institutional Cluster | $41.53 $35.28 | ▼ −15.05% | ▼ −14.13% | $31.02 (−25.31%) |
Jun 12, 2026 16w ago | Press Release | $33.10 $38.87 | ▲ +17.43% | ▲ +15.65% | $31.02 (−6.28%) |
Jun 12, 2026 16w ago | Press Release | $33.10 $38.87 | ▲ +17.43% | ▲ +15.65% | $31.02 (−6.28%) |
May 30, 2026 17w ago | Press Release | $34.81 $38.70 | ▲ +11.18% | ▲ +12.47% | $31.02 (−10.89%) |
May 28, 2026 18w ago | Press Release | $35.38 $38.10 | ▲ +7.69% | ▲ +10.83% | $31.02 (−12.32%) |
May 5, 2026 21w ago | 8-K | $36.98 $32.76 | ▼ −11.41% | ▼ −16.37% | $31.02 (−16.12%) |
Apr 17, 2026 24w ago | Press Release | $37.25 $34.19 | ▼ −8.21% | ▼ −13.59% | $31.02 (−16.72%) |
Apr 1, 2026 26w ago | Press Release | $35.24 $35.87 | ▲ +1.79% | ▼ −7.93% | $31.02 (−11.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access